Sartorius Stedim Biotech opens new centre for bioprocess innovation in Marlborough, US

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.

This state-of-the-art facility is designed to foster collaboration, co-development and learning on site with customers and other external innovation partners, applying Sartorius' latest technologies in real-life bioprocess workflows.  

The 63,000-square-foot facility houses research and service laboratories, as well as facilities for customer demos and trainings. Dedicated expert teams will offer process development, optimisation and validation services. Currently hosting a team of 50 scientists and product developers, the new hub will have the capacity to accommodate more than 120 internal and external bioprocessing experts.

In 2025, Sartorius Stedim Biotech will add two multi-modality GMP suites, operating on Sartorius workflows and equipment. The suites will allow customers to extend their process development projects with Sartorius into the early stages of clinical production. With this, the company further expands its solution offering with a focus on developing novel manufacturing processes for next generation therapeutics.

Sartorius Stedim Biotech has expanded its presence in the area in the recent past. Initially operating from a shared lab in the Seaport District in Boston, the company acquired Marlborough-based purification expert WaterSep BioSeparations in 2020 and opened a new Customer Interaction Center (CIC) for Bioprocess Equipment in 2021, both located near the new Center for Bioprocess Innovation. More than 100 employees work at three sites in Marlborough, and around 1,800 people for Sartorius Stedim Biotech in North America.